glp-1 physiology informs the pharmacotherapy of obesity What is pipeline for future medications for obesity? GLP-1-based therapies for diabetes, obesity

By activating GLP-1 receptors, these agents enhance glucose-dependent insulin secretion, suppress appetite, delay gastric emptying, and improve insulin sensitivity [12, 13]

The good news is that sulfur burps typically fade as your body adapts, and several evidence-based strategies can reduce their frequency and intensity

Weight loss on tirzepatide must remain gradual and medically supervised to prevent complications such as dehydration or electrolyte imbalance

Future research should focus on: Developing oral formulations

However, we also have a constant, low level of circulating GLP-1 even when fasting.[ref][ref] This directly ties into the gut microbiome